APA (7th ed.) Citation

Merlo, C. A., Romdhani, H., DerSarkissian, M., Muthukumar, A., McGarry, L. J., Lou, Y., & Van Brunt, K. (2026). Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19. Pulmonary Therapy, 12(2), 599. https://doi.org/10.1007/s41030-026-00363-0

Chicago Style (17th ed.) Citation

Merlo, Christian A., Hela Romdhani, Maral DerSarkissian, Aruna Muthukumar, Lisa J. McGarry, Yiyue Lou, and Kate Van Brunt. "Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated Versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US During COVID-19." Pulmonary Therapy 12, no. 2 (2026): 599. https://doi.org/10.1007/s41030-026-00363-0.

MLA (9th ed.) Citation

Merlo, Christian A., et al. "Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated Versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US During COVID-19." Pulmonary Therapy, vol. 12, no. 2, 2026, p. 599, https://doi.org/10.1007/s41030-026-00363-0.